FDA Breakthrough Device · Pivotal Phase 3 Trial Underway

Advancing a Pivotal-Stage Platform for Parkinson’s Disease

Celeste is a novel photo-neuromodulation therapy designed to engage neural signaling pathways implicated in both motor and non-motor symptoms of PD.

Explore the Clinical Program
For Investors

Celeste® is an investigational device and has not been cleared or approved for commercial distribution.

Dopamine Isn’t the Whole Story

Celeste Addresses Broader Dysfunction in PD.

For decades, therapeutic innovation in Parkinson’s disease has focused on dopaminergic pathways that improve motor symptoms. Many of these treatments target dopamine and introduce side effects and motor complications.

Despite best medical treatment, functional impairment persists in areas including reduced motor function and debilitating non-motor symptoms such as sleep disturbances, fatigue, depression, anxiety, cognitive impairment, and quality of life. These often progress and intensify independently of motor control.

There are currently no FDA-approved therapies specifically indicated for these symptoms.

Celeste is a once-daily, non-invasive and non-dopaminergic treatment that has demonstrated large, clinically meaningful motor and non-motor improvements on top of best medical care.

Learn How the Technology Works

Addressing the Unmet Needs of Parkinson’s Disease

Despite Best Medical Care, Functional Impairment Persists

%

Motor Function

%

Motor Function

%

Sleep Disturbances

%

Chronic Fatigue

%

Depression

%

Anxiety

%

Cognitive Impairments

No FDA-approved therapies specifically indicated for any of these domains in Parkinson's disease

*Based on published studies in treated Parkinson’s disease populations.

The Unmet Need

Treatment of many symptoms remains a whitespace

A variety of symptoms affect the majority of people living with Parkinson’s disease and frequently remain insufficiently addressed by current therapies.

Despite advances in dopaminergic treatment, patients continue to experience persistent challenges with motor function, sleep, fatigue, mood, cognition, and other domains that significantly impact daily function and quality of life.

Celeste is being evaluated as a novel therapeutic approach designed to engage neural signaling pathways implicated in these domains.

Major Life Impacts
  • Sleep disruption
  • Fatigue and daytime impairment
  • Mood and cognitive decline
  • Loss of independence
  • Inability to work
  • Reduced quality of life
Photo Nueromodulation

A New Therapeutic Category in Parkinson’s Disease

Non-invasive photo-neuromodulation targets neural signaling pathways involved in non-motor symptom domains.

Celeste is designed to engage neural signaling pathways beyond dopamine, offering a differentiated therapeutic approach for Parkinson’s disease.

Learn How the Technology Works
FDA Breakthrough Device Designation

Recognizing the potential of Celeste to address a significant unmet clinical need in Parkinson’s disease.
Learn More…

Fully Enrolled 350-Patient Pivotal Trial

350-patient randomized clinical study evaluating Celeste in Parkinson’s disease. Topline data expected in 2026.
Learn More…

Our Mission

Born from deep conviction that neural signaling can be restored

Learn More About PhotoPharmics

Clinical Progress & Publications

Corporate updates and peer-reviewed developments supporting the scientific foundation and disciplined clinical advancement of Celeste.

Explore More